Benzimidazole-derived Compounds Designed for Different Targets of Alzheimer's Disease

Gulcan H. O., Mavideniz A., Sahin M. F., ERDOĞAN ORHAN İ.

CURRENT MEDICINAL CHEMISTRY, vol.26, no.18, pp.3260-3278, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 26 Issue: 18
  • Publication Date: 2019
  • Doi Number: 10.2174/0929867326666190124123208
  • Journal Name: CURRENT MEDICINAL CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.3260-3278
  • Keywords: Benzimidazoles, cholinesterase inhibition, H-3 receptors, PPAR, BACE, gamma-secretase, glutaminyl cyclase, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, HISTAMINE H-3 RECEPTOR, BIOLOGICAL EVALUATION, GLUTAMINYL CYCLASE, H3 RECEPTOR, 1H-BENZIMIDAZOLE DERIVATIVES, NEUROFIBRILLARY TANGLES, NATURAL ANTIOXIDANTS, EMERGING TARGETS, DOWN-SYNDROME
  • Gazi University Affiliated: Yes

Abstract

Benzimidazole scaffold has been efficiently used for the design of various pharmacologically active molecules. Indeed, there are various benzimidazole drugs, available today, employed for the treatment of different diseases. Although there is no benzimidazole moiety containing a drug used in clinic today for the treatment of Alzheimer's Disease (AD), there have been many benzimidazole derivative compounds designed and synthesized to act on some of the validated and non-validated targets of AD. This paper aims to review the literature to describe these benzimidazole containing molecules designed to target some of the biochemical cascades shown to be involved in the development of AD.